On the back of a €18.5 million fundraising, Kither Biotech Srl plans to accelerate development of a candidate product for cystic fibrosis. The product, KIT2014, is currently in preclinical studies which are expected to complete in 2022. Soon thereafter, it will move on to a Phase 1/2A trial. KIT2014 is being developed as an add-on to the current standard of care. It is delivered directly to the lungs as an inhaled therapy. It works by modulating cyclic adenosine monophosphate levels inside cells.
